Chargement en cours...
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
PURPOSE OF REVIEW: Small molecule inhibitors targeting the CCR5 coreceptor represent a new class of drugs for treating HIV-1 infection. Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials. Understanding how resistance to these drugs develops and is diagnosed is essential...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2896203/ https://ncbi.nlm.nih.gov/pubmed/19339950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COH.0b013e3283223d46 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|